GlassScriptPhysician profile
Mallory Halpin
NPI 1265969851
$7,868.21
in general payments reported to CMS, 2019-2025
28 companies · $4,029 in 2025
The $4,029 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.72 · 2023: $1,676 · 2024: $2,114 · 2025: $4,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,569 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,568.56 |
| Education | $249.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,732.04 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,162.96 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $949.16 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $425.54 | 2023-2025 | Glassia |
| Grifols USA, LLC | $413.04 | 2023-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $356.69 | 2021-2025 | Wakix |
| Genzyme Corporation | $352.70 | 2024-2025 | |
| Amgen INC. | $339.93 | 2023-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.99 | 2023-2025 | Ofev, Jascayd |
| Mallinckrodt Hospital Products INC. | $265.85 | 2023-2025 | Acthar |
| Jazz Pharmaceuticals INC. | $250.72 | 2023-2025 | |
| Insmed, INC. | $184.33 | 2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $170.58 | 2023 | Cresemba |
| Viatris Specialty LLC | $163.49 | 2025 | Yupelri |
| Philips North America LLC | $124.29 | 2023-2024 | (Ak6) Vest Therapy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $106.20 | 2021-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $88.27 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $60.41 | 2023-2025 | Sunosi |
| Lilly USA, LLC | $57.09 | 2025 | Zepbound |
| Genentech USA, INC. | $54.72 | 2023-2024 | Xolair |
| Verona Pharma, INC. | $53.61 | 2025 | Ohtuvayre |
| Pfizer INC. | $36.66 | 2024-2025 | |
| United Therapeutics Corporation | $32.45 | 2025 | Tyvaso |
| Ani Pharmaceuticals, INC. | $29.05 | 2025 | Purified Cortrophin Gel |
| Kedrion Biopharma, INC. | $22.89 | 2024 | Koate, Gammaked, Kedrab |
| Merck Sharp & Dohme LLC | $22.34 | 2023 | |
| Resmed Corp | $14.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Halpin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.